Lori L Billinghurst1, Lauren A Beslow2, Nicholas S Abend2, Michael Uohara2, Laura Jastrzab2, Daniel J Licht2, Rebecca N Ichord2. 1. From the Division of Neurology (L.L.B., L.A.B., N.S.A., L.J., D.J.L., R.N.I.), The Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania; and Temple University School of Medicine (M.U.), Philadelphia, PA. billinghurstl@email.chop.edu. 2. From the Division of Neurology (L.L.B., L.A.B., N.S.A., L.J., D.J.L., R.N.I.), The Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania; and Temple University School of Medicine (M.U.), Philadelphia, PA.
Abstract
OBJECTIVE: To determine the cumulative incidence and clinical predictors of remote symptomatic seizures and epilepsy after pediatric arterial ischemic stroke (AIS). METHODS: We performed a retrospective analysis of 218 participants with neonatal AIS (NAIS), presumed perinatal AIS (PPAIS), and childhood AIS (CAIS) from a single-center prospective consecutive cohort enrolled from 2006 to 2014. Medical records were reviewed for timing, semiology, and treatment of acute symptomatic seizures, remote symptomatic seizures (RSS), and epilepsy. Cumulative incidence of RSS and epilepsy were assessed using survival analysis. RESULTS: Acute symptomatic seizures occurred in 94% of NAIS (n = 70/74) and 17% of CAIS (n = 18/105). Younger children were more likely to present with seizures at stroke ictus, and acute symptomatic seizures were predictive of later RSS and epilepsy in CAIS. Median follow-up for the entire cohort was 34 months, interquartile range 44.9 months (16.3-61.2). Estimated cumulative incidence of RSS at 2 years was 19% in NAIS, 24% in PPAIS, and 7% in CAIS. Estimated cumulative incidence of epilepsy at 2 years was 11% in NAIS, 19% in PPAIS, and 7% in CAIS. The median time to these outcomes was <2 years in all stroke subtypes. Among participants developing epilepsy (n = 34), seizures were often well-controlled at last follow-up with median Engel class of ≤2 (<1 seizure/month). CONCLUSIONS: RSS and epilepsy are important neurologic sequelae of pediatric AIS. Children with perinatal stroke and CAIS with acute symptomatic seizures are at increased risk of these outcomes. These cohorts need further study to identify biomarkers and potential therapeutic targets for epileptogenesis.
OBJECTIVE: To determine the cumulative incidence and clinical predictors of remote symptomatic seizures and epilepsy after pediatric arterial ischemic stroke (AIS). METHODS: We performed a retrospective analysis of 218 participants with neonatal AIS (NAIS), presumed perinatal AIS (PPAIS), and childhood AIS (CAIS) from a single-center prospective consecutive cohort enrolled from 2006 to 2014. Medical records were reviewed for timing, semiology, and treatment of acute symptomatic seizures, remote symptomatic seizures (RSS), and epilepsy. Cumulative incidence of RSS and epilepsy were assessed using survival analysis. RESULTS: Acute symptomatic seizures occurred in 94% of NAIS (n = 70/74) and 17% of CAIS (n = 18/105). Younger children were more likely to present with seizures at stroke ictus, and acute symptomatic seizures were predictive of later RSS and epilepsy in CAIS. Median follow-up for the entire cohort was 34 months, interquartile range 44.9 months (16.3-61.2). Estimated cumulative incidence of RSS at 2 years was 19% in NAIS, 24% in PPAIS, and 7% in CAIS. Estimated cumulative incidence of epilepsy at 2 years was 11% in NAIS, 19% in PPAIS, and 7% in CAIS. The median time to these outcomes was <2 years in all stroke subtypes. Among participants developing epilepsy (n = 34), seizures were often well-controlled at last follow-up with median Engel class of ≤2 (<1 seizure/month). CONCLUSIONS: RSS and epilepsy are important neurologic sequelae of pediatric AIS. Children with perinatal stroke and CAIS with acute symptomatic seizures are at increased risk of these outcomes. These cohorts need further study to identify biomarkers and potential therapeutic targets for epileptogenesis.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Renate M Arntz; Loes C A Rutten-Jacobs; Noortje A M Maaijwee; Hennie C Schoonderwaldt; Lucille D A Dorresteijn; Ewoud J van Dijk; Frank-Erik de Leeuw Journal: Stroke Date: 2015-07-02 Impact factor: 7.914
Authors: Timothy J Bernard; Marilyn J Manco-Johnson; Warren Lo; Mark T MacKay; Vijeya Ganesan; Gabrielle DeVeber; Neil A Goldenberg; Jennifer Armstrong-Wells; Michael M Dowling; E Steve Roach; Mark Tripputi; Heather J Fullerton; Karen L Furie; Susanne M Benseler; Lori C Jordan; Adam Kirton; Rebecca Ichord Journal: Stroke Date: 2011-12-08 Impact factor: 7.914
Authors: Hannah C Glass; Karen J Hong; Elizabeth E Rogers; Rita J Jeremy; Sonia L Bonifacio; Joseph E Sullivan; A James Barkovich; Donna M Ferriero Journal: Pediatr Res Date: 2011-11 Impact factor: 3.756
Authors: Jithangi Wanigasinghe; Susan M Reid; Mark T Mackay; Dinah S Reddihough; A Simon Harvey; Jeremy L Freeman Journal: Dev Med Child Neurol Date: 2010-11 Impact factor: 5.449
Authors: N S Abend; A M Gutierrez-Colina; A A Topjian; H Zhao; R Guo; M Donnelly; R R Clancy; D J Dlugos Journal: Neurology Date: 2011-02-09 Impact factor: 9.910
Authors: Christine K Fox; Hannah C Glass; Stephen Sidney; Daniel H Lowenstein; Heather J Fullerton Journal: Ann Neurol Date: 2013-08 Impact factor: 10.422
Authors: Aleksandra Mineyko; Adam Kirton; Lori Billinghurst; Nana Nino Tatishvili; Max Wintermark; Gabrielle deVeber; Christine Fox Journal: Pediatr Neurol Date: 2019-10-18 Impact factor: 3.372